Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer

Jonathan Riess; Aaron C. Logan; Yelena Krupitskaya; Sukhmani Padda; Christelle Clément-Duchne; Kristen Ganjoo; A. Dimitrios Colevas; Melanie San Pedro-Salcedo; Calvin J. Kuo; Heather A. Wakelee

doi:10.3109/07357907.2012.656862

Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer

Jonathan Riess, Aaron C. Logan, Yelena Krupitskaya, Sukhmani Padda, Christelle Clément-Duchne, Kristen Ganjoo, A. Dimitrios Colevas, Melanie San Pedro-Salcedo, Calvin J. Kuo, Heather A. Wakelee

Research output: Contribution to journal › Article

3 Scopus citations

Abstract

We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.

Original language	English (US)
Pages (from-to)	231-235
Number of pages	5
Journal	Cancer Investigation
Volume	30
Issue number	3
DOIs	https://doi.org/10.3109/07357907.2012.656862
State	Published - Mar 2012
Externally published	Yes

Keywords

Angiogenesis
Cancer biomarkers
Clinical trials
Non-small cell lung cancer
VEGF

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.3109/07357907.2012.656862

Fingerprint Dive into the research topics of 'Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Riess, J., Logan, A. C., Krupitskaya, Y., Padda, S., Clément-Duchne, C., Ganjoo, K., Colevas, A. D., Pedro-Salcedo, M. S., Kuo, C. J., & Wakelee, H. A. (2012). Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Investigation, 30(3), 231-235. https://doi.org/10.3109/07357907.2012.656862

Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. / Riess, Jonathan; Logan, Aaron C.; Krupitskaya, Yelena; Padda, Sukhmani; Clément-Duchne, Christelle; Ganjoo, Kristen; Colevas, A. Dimitrios; Pedro-Salcedo, Melanie San; Kuo, Calvin J.; Wakelee, Heather A.

In: Cancer Investigation, Vol. 30, No. 3, 03.2012, p. 231-235.

Research output: Contribution to journal › Article

Riess, Jonathan ; Logan, Aaron C. ; Krupitskaya, Yelena ; Padda, Sukhmani ; Clément-Duchne, Christelle ; Ganjoo, Kristen ; Colevas, A. Dimitrios ; Pedro-Salcedo, Melanie San ; Kuo, Calvin J. ; Wakelee, Heather A. / Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. In: Cancer Investigation. 2012 ; Vol. 30, No. 3. pp. 231-235.

@article{befc03314f714584a0002a53ff5d63b6,

title = "Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer",

abstract = "We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.",

keywords = "Angiogenesis, Cancer biomarkers, Clinical trials, Non-small cell lung cancer, VEGF",

author = "Jonathan Riess and Logan, {Aaron C.} and Yelena Krupitskaya and Sukhmani Padda and Christelle Cl{\'e}ment-Duchne and Kristen Ganjoo and Colevas, {A. Dimitrios} and Pedro-Salcedo, {Melanie San} and Kuo, {Calvin J.} and Wakelee, {Heather A.}",

year = "2012",

month = mar,

doi = "10.3109/07357907.2012.656862",

language = "English (US)",

volume = "30",

pages = "231--235",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer

AU - Riess, Jonathan

AU - Logan, Aaron C.

AU - Krupitskaya, Yelena

AU - Padda, Sukhmani

AU - Clément-Duchne, Christelle

AU - Ganjoo, Kristen

AU - Colevas, A. Dimitrios

AU - Pedro-Salcedo, Melanie San

AU - Kuo, Calvin J.

AU - Wakelee, Heather A.

PY - 2012/3

Y1 - 2012/3

N2 - We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.

AB - We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.

KW - Angiogenesis

KW - Cancer biomarkers

KW - Clinical trials

KW - Non-small cell lung cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84857616374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857616374&partnerID=8YFLogxK

U2 - 10.3109/07357907.2012.656862

DO - 10.3109/07357907.2012.656862

M3 - Article

C2 - 22360362

AN - SCOPUS:84857616374

VL - 30

SP - 231

EP - 235

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -